| | Antigen combinations | % (n/total) |
| | One antigen | | | p53 | 48.0 (120/250) | | SP17 | 68.9 (173/251) | | Survivin | 90.0 (208/231) | | WT1 | 56.3 (129/229) | | NY-ESO-1 | 11.0 (27/246) |
| | Two antigens | | | p53, SP17 | 84.2 (203/241) | | p53, survivin | 95.5 (214/224) | | p53, WT1 | 73.1 (163/223) | | p53, NY-ESO-1 | 52.7 (125/237) | | SP17, surviving | 94.7 (215/227) | | SP17, WT1 | 82.3 (186/226) | | SP17, NY-ESO-1 | 74.0 (179/242) | | survivin, WT1 | 93.0 (212/228) | | survivin, NY-ESO-1 | 90.8 (208/229) | | WT1, NY-ESO-1 | 60.3 (138/229) |
| | Three antigens | | | p53, SP17, survivin | 97.7 (217/222) | | p53, SP17, WT1 | 91.4 (202/221) | | p53, SP17, NY-ESO-1 | 86.4 (203/235) | | p53, survivin, WT1 | 95.9 (213/222) | | p53, survivin, NY-ESO-1 | 95.5 (213/223) | | p53, WT1, NY-ESO-1 | 74.4 (166/223) | | SP17, survivin, WT1 | 96.0 (216/225) | | SP17, survivin, NY-ESO-1 | 95.6 (216/226) | | SP17, WT1, NY-ESO-1 | 84.5 (191/226) | | survivin, WT1, NY-ESO-1 | 93.4 (213/228) |
| | Four antigens | | | p53, SP17, survivin, WT1 | 98.2 (216/220) | | p53, SP17, survivin, NY-ESO-1 | 97.7 (216/221) | | p53, SP17, WT1, NY-ESO-1 | 92.3 (204/221) | | p53, survivin, WT1, NY-ESO-1 | 95.9 (213/222) | | SP17, survivin, WT1, NY-ESO-1 | 96.4 (217/225) |
| | All antigens | | | p53, SP17, survivin, WT1, NY-ESO-1 | 98.2 (216/220) |
|
|
